NANOPARTICLE DELIVERY OF THE HISTONE DEACETYLASE INHIBITOR PXD101 FACILITATES BLADDER CANCER CELL UPTAKE AND CYTOTOXICITY

被引：0

作者：

Kaimakliotis, Hristos Z.

Martin, Darryl T.

Hoimes, Christopher J.

Cheng, Christopher C.

Liu, Jingchun

Kelly, Wm. Kevin

Tew, Gregory N.

Saltzman, W. Mark

Weiss, Robert M.

机构：

来源：

JOURNAL OF UROLOGY | 2011年 / 185卷 / 04期

关键词：

D O I：

10.1016/j.juro.2011.02.1180

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

1358

引用

页码：E542 / E542

页数：1

共 50 条

[41] Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer
Martin, Darryl T.
Hoimes, Christopher J.
Kaimakliotis, Hristos Z.
Cheng, Christopher J.
Zhang, Ke
Liu, Jingchun
Wheeler, Marcia A.
Kelly, W. Kevin
Tew, Greg N.
Saltzman, W. Mark
Weiss, Robert M.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2013, 9 (08) : 1124 - 1134
[42] A phase II trial of the histone deacetylase inhibitor Belinostat (PXD101) in patients with platinum resistant epithelial ovarian tumors and micropapillary/borderline (LMP) ovarian tumors. A trial of the PMH Phase II Consortium
Mackay, Helen J.
Hirte, Hal
Covens, Al
MacAlpine, Katrina
Wang, Lisa
Tsao, Ming
Pan, James
Zweibel, James
Oza, Amit M.
MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3388S - 3388S
[43] Gene profiling of PXD-101, a novel hydroxamate type inhibitor of histone deacetylase, leads to identification of aurora kinase inhibition.
Hose, C
Shoemaker, R
Monks, A
CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9152S - 9152S
[44] A phase II trial of the histone deacetylase inhibitor belinostat (PXD101) in patients with platinum resistant epithelial ovarian tumors and micropapillary/borderline (LMP) ovarian tumors. A PMH phase II consortium trial
Mackay, H.
Hirte, H. W.
Covens, A.
MacAlpine, K.
Wang, L.
Tsao, M. S.
Pan, J.
Zwiebel, J. A.
Oza, A. M.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[45] The Histone Deacetylase Inhibitor Trichostatin A Synergistically Resensitizes a Cisplatin Resistant Human Bladder Cancer Cell Line
Yoon, Cheol Yong
Park, Mi Jung
Lee, Jung Sun
Lee, Sang Chul
Oh, Jong Jin
Park, Hongzoo
Chung, Chang Wook
Abdullajanov, Murod M.
Jeong, Seong Jin
Hong, Sung Kyu
Byun, Seok Soo
Lee, Eun Sik
Lee, Sang Eun
JOURNAL OF UROLOGY, 2011, 185 (03): : 1102 - 1111
[46] Phase II multicenter trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) for patients (pts) with transitional cell carcinoma (TCC) of the bladder
Barriuso, J.
Daugaard, G.
Frentzas, S.
Fuglsang, L.
Glasspool, R.
Krarup-Hansen, A.
Jones, R. J.
Lassen, U.
Sengelov, L.
De Bono, J. S.
EJC SUPPLEMENTS, 2008, 6 (12): : 67 - 68
[47] A NANOPARTICLE PLATFORM FOR INTRATHECAL DELIVERY OF THE HISTONE DEACETYLASE INHIBITOR (HDACI) PANOBINOSTAT IN METASTATIC OR RECURRENT MEDULLOBLASTOMA
Chaudhuri, Sauradip
Mohammad, Afroz S.
Zhang, Wenqui
Baker, Cassandra
Broughton, Colton W.
Fowler, Martha J.
Stabenfeldt, Sarah E.
Wechsler-Reya, Robert J.
Sandberg, David I.
Elmquist, William F.
Sirianni, Rachael W.
NEURO-ONCOLOGY, 2020, 22 : 285 - 285
[48] STUDY ON THE SYNERGIC EFFECT AND MECHANISM OF THE HISTONE-DEACETYLASE INHIBITOR, TRICHOSTATIN A AND GEMCITABINE IN BLADDER CANCER CELL LINES
Jeon, Hwang Gyun
Yoon, Cheol Yong
Jeong, Chang Wook
Jeong, Seong Jin
Doo, Seung Hwan
Hong, Sung Kyu
Byun, Seok-Soo
Lee, Sang Eun
JOURNAL OF UROLOGY, 2010, 183 (04): : E448 - E448
[49] Synergy of Histone-Deacetylase Inhibitor AR-42 with Cisplatin in Bladder Cancer
Li, David R.
Zhang, Hanwei
Peek, Elizabeth
Wang, Song
Du, Lin
Li, Gang
Chin, Arnold I.
JOURNAL OF UROLOGY, 2015, 194 (02): : 547 - 555
[50] Targeting novel nuclear receptors with histone deacetylase inhibitor combination therapy in bladder cancer
Abedin, SA
Veerakumarasivam, A
Kelly, J
Neal, DE
Mills, I
Campbell, M
EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 36 - 36

← 1 2 3 4 5 →